title: Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma.
abstract: In this study, we describe characteristic chromosomal alterations in a consecutive series of 96 serous ovarian tumors by comparative genomic hybridization. We analyze their association with different pathways of progression, histological grade, and clinical outcome. The most striking difference between low-grade and high-grade serous carcinomas was seen in a higher incidence of chromosomal gains at 3q and 20q and losses of 13q in the high-grade carcinomas. In addition, high-level amplifications were significantly more frequent in high-grade carcinomas, specifically involving regions on 3q and 8q. Chromosomal amplifications of 19p and 19q and losses of 4q and 5q were among the most frequent changes found in both low-grade and high-grade carcinomas, distinguishing them from borderline tumors, which had very few recurrent alterations. The most significant impact on survival of patients with invasive carcinomas Stage II-IV was observed for high-level amplifications of regions on 8q (mean overall survival (OS) 69 versus 27 months, P = 0.0006). Interestingly, low-level gains on 8q do not show any impact compared to cases with no alteration. Surprisingly, chromosomal losses on 5q had a protective impact (mean OS 36 versus 76 months, P = 0.0007). Combination of both parameters resulted in two risk groups. Low risk: loss on 5q, no amplification on 8q (mean OS 84 months); high risk: no loss on 5q, amplification on 8q (mean OS 26 months). This difference is even more pronounced, if only cases with residual tumor of less than 2 cm are included, resulting in a 5-year survival of 100% and 0% (P = 0.0005).
authors.affiliation: Institute of Pathology, University of Muenster, Muenster, Germany. a.staebler@uni-muenster.de
authors.forename: Annette
authors.initials: A
authors.lastname: Staebler
authors.forename: Bianca
authors.initials: B
authors.lastname: Karberg
authors.forename: Juliane
authors.initials: J
authors.lastname: Behm
authors.forename: Petra
authors.initials: P
authors.lastname: Kuhlmann
authors.forename: Ulrike
authors.initials: U
authors.lastname: Neubert
authors.forename: Hartmut
authors.initials: H
authors.lastname: Schmidt
authors.forename: Eberhard
authors.initials: E
authors.lastname: Korsching
authors.forename: Horst
authors.initials: H
authors.lastname: Bürger
authors.forename: Ralph
authors.initials: R
authors.lastname: Lelle
authors.forename: Ludwig
authors.initials: L
authors.lastname: Kiesel
authors.forename: Werner
authors.initials: W
authors.lastname: Böcker
authors.forename: Ie-Ming
authors.initials: IeM
authors.lastname: Shih
authors.forename: Olaf
authors.initials: O
authors.lastname: Buchweitz
mesh_terms: D002869:Chromosome Aberrations; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D018284:Cystadenocarcinoma, Serous / Q000235:genetics; D018293:Cystadenoma, Serous / Q000235:genetics; D005260:Female; D005784:Gene Amplification; D006801:Humans; D009693:Nucleic Acid Hybridization; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000235:genetics*; D011379:Prognosis; D015996:Survival Rate